TY - JOUR T1 - Incidence, predictors and prognostic significance of thromboembolic disease in patients with advanced <em>ALK</em>-rearranged non-small-cell lung cancer JF - European Respiratory Journal JO - Eur Respir J DO - 10.1183/13993003.02431-2017 SP - 1702431 AU - Jon Zugazagoitia AU - Mercedes Biosca AU - Julio Olivera AU - María Eugenia Olmedo AU - Manuel Dómine AU - Ernest Nadal AU - José Carlos Ruffinelli AU - Nerea Muñoz AU - Ana María Luna AU - Berta Hernández AU - Maite Martínez AU - Iria Gallego AU - Eva Martínez de Castro AU - Carme Font AU - Virginia Calvo AU - Virginia Martínez-Marín AU - Jesús Corral AU - Esther Noguerón AU - Rebeca Mondéjar AU - Ignacio García Escobar AU - Carmen Salvador-Coloma AU - Óscar Juan AU - Manuel Sánchez Cánovas AU - Javier Valdivia AU - M. Pilar Ochoa AU - Rafael López Castro AU - Berta Obispo AU - Cristina Pangua AU - María Sereno AU - Lourdes Fernández Franco AU - Xabier Mielgo AU - Julia Calzas AU - Ana Blasco AU - Francisco Aparisi AU - Luis Chara AU - Juan Francisco Grau AU - Marta Soares AU - Ana Gómez AU - Victor Zenzola AU - Marcial García-Morillo AU - Diego Cacho AU - Asunción Díaz-Serrano AU - Carlos Aguado AU - Santiago Ponce-Aix AU - Jose Luis González-Larriba AU - Andrés J. Muñoz AU - David Lora AU - Luis Paz-Ares AU - Aránzazu Manzano Y1 - 2018/01/01 UR - http://erj.ersjournals.com/content/early/2018/03/01/13993003.02431-2017.abstract N2 - Thromboembolic disease is fairly common in patients with lung cancer [1–3]. This incidence seems to be higher in patients with lung adenocarcinomas [4], with approximately 15% of those with advanced-stage disease developing venous thromboembolisms (VTE) during the whole course of their disease [5–7]. Pulmonary adenocarcinomas are a heterogeneous group of diseases, that can be stratified according to the presence major oncogenic driver alterations. Anaplastic lymphoma kinase (ALK) rearrangements are detected in approximately 4% of these cases [8]. Isolated reports have suggested that patients bearing ALK-rearranged tumors might have a higher than expected incidence of thromboembolisms [9, 10]. In the present study, we have analyzed the incidence, predictors and prognostic significance of thromboembolic events in a large, multi-institutional and homogeneous cohort of advanced-stage patients with ALK-rearranged lung cancers from Spain and Portugal. Our primary objective was to estimate the incidence of thromboembolic events and their association with overall survival (OS) in these patients.High incidence and prognostic relevance of thromboembolic disease in patients with ALK-rearranged NSCLCsFootnotesThis manuscript has recently been accepted for publication in the European Respiratory Journal. It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJ online. Please open or download the PDF to view this article.Conflict of interest: Dr. ZUGAZAGOITIA has nothing to disclose.Conflict of interest: Dr. Biosca reports personal fees from LEO-PHARMA, personal fees from SANOFI, outside the submitted work.Conflict of interest: Dr. OLIVEIRA has nothing to disclose.Conflict of interest: Dr. Olmedo has nothing to disclose.Conflict of interest: Dr. Domine has nothing to disclose.Conflict of interest: Dr. NADAL has nothing to disclose.Conflict of interest: Dr. Ruffinellli has nothing to disclose.Conflict of interest: Dr. Muñoz has nothing to disclose.Conflict of interest: Dr. LUNA has nothing to disclose.Conflict of interest: Dr. Hernández has nothing to disclose.Conflict of interest: Dr. Martínez has nothing to disclose.Conflict of interest: Dr. GALLEGO has nothing to disclose.Conflict of interest: Dr. MARTINEZ DE CASTRO has nothing to disclose.Conflict of interest: Dr. FONT has nothing to disclose.Conflict of interest: Dr. Calvo has nothing to disclose.Conflict of interest: Dr. MARTINEZ-MARIN has nothing to disclose.Conflict of interest: Dr. Corral has nothing to disclose.Conflict of interest: Dr. NOGUERON has nothing to disclose.Conflict of interest: Dr. MONDEJAR has nothing to disclose.Conflict of interest: Dr. García Escobar has nothing to disclose.Conflict of interest: Dr. Salvador-Coloma has nothing to disclose.Conflict of interest: Dr. Juan-vidal has nothing to disclose.Conflict of interest: Dr. Sánchez Cánovas has nothing to disclose.Conflict of interest: Dr. VALDIVIA has nothing to disclose.Conflict of interest: Dr. OCHOA has nothing to disclose.Conflict of interest: Dr. Lopez Castro has nothing to disclose.Conflict of interest: Dr. OBISPO has nothing to disclose.Conflict of interest: Dr. Pangua has nothing to disclose.Conflict of interest: Dr. SERENO has nothing to disclose.Conflict of interest: Dr. FERNANDEZ FRANCO has nothing to disclose.Conflict of interest: Dr. Mielgo has nothing to disclose.Conflict of interest: Dr. CALZAS has nothing to disclose.Conflict of interest: Dr. Blasco has nothing to disclose.Conflict of interest: Dr. APARISI has nothing to disclose.Conflict of interest: Dr. Chara has nothing to disclose.Conflict of interest: Dr. Grau has nothing to disclose.Conflict of interest: Dr. SOARES has nothing to disclose.Conflict of interest: Dr. Gomez has nothing to disclose.Conflict of interest: Dr. Zenzola has nothing to disclose.Conflict of interest: Dr. García-Morillo has nothing to disclose.Conflict of interest: Dr. CACHO has nothing to disclose.Conflict of interest: Dr. DIAZ SERRANO has nothing to disclose.Conflict of interest: Dr. AGUADO has nothing to disclose.Conflict of interest: Dr. PONCE-AIX has nothing to disclose.Conflict of interest: Dr. GONZALEZ-LARRIBA has nothing to disclose.Conflict of interest: Dr. MUÑOZ has nothing to disclose.Conflict of interest: Dr. LORA has nothing to disclose.Conflict of interest: Dr. Paz-Ares reports other from Roche, other from Lilly, other from Bristol Meyers Squibb, other from Merck &amp; Sharp D., other from Boehringer Ing., other from Pfizer, other from AstraZeneca, other from Amgem, other from Novartis, outside the submitted work.Conflict of interest: Dr. MANZANO reports personal fees from PHARMAMAR, personal fees from ROCHE, personal fees from ASTRA ZENECA, outside the submitted work. ER -